Showing 7161-7170 of 9357 results for "".
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Interactive Education Resource for Residents Now Availablehttps://practicaldermatology.com/news/20120716-interactive_education_resource_for_residents_now_available/2459772/
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- ESCD 2026: New Data Show Ongoing Burden of Chronic Hand Eczemahttps://practicaldermatology.com/news/escd-2026-new-data-on-chronic-hand-eczema-burden-and-unmet-needs/2487581/LEO Pharma will present new data at the European Society of Contact Dermatitis (ESCD) Congress 2026 in Copenhagen highlighting the significant burden chronic hand eczema (CHE) continues to place on patients across different stages of life, according to a press release from the manufacturer. The p
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Comparative Study Finds No Significant Melanoma Mortality Reduction From German Screening Initiativehttps://practicaldermatology.com/news/comparative-study-finds-no-significant-melanoma-mortality-reduction-from-german-screening-initiative/2487471/A study of a German nationwide skin cancer screening (SCS) program showed reduced melanoma mortality compared with neighboring European countries that do not have population-based screening programs. Germany launched its nationwide SCS program in 2008, which included adults aged 35 years a